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Abstract
Question
Should patients with newly-diagnosed metastatic brain
tumors undergo open surgical resection versus whole brain
radiation therapy (WBRT) and/or other treatment modalities
such as radiosurgery, and in what clinical settings?
Target population
These recommendations apply to adults with a newly diag-
nosedsinglebrainmetastasisamenabletosurgicalresection.
Recommendations
Surgical resection plus WBRT versus surgical resection
alone
Level 1 Surgical resection followed by WBRT represents a
superior treatment modality, in terms of improving tumor
control at the original site of the metastasis and in the brain
overall, when compared to surgical resection alone.
Surgical resection plus WBRT versus SRS – WBRT
Level 2 Surgical resection plus WBRT, versus stereotactic
radiosurgery (SRS) plus WBRT, both represent effective
treatment strategies, resulting in relatively equal survival
rates. SRS has not been assessed from an evidence-based
standpoint for larger lesions ([3 cm) or for those causing
signiﬁcant mass effect ([1 cm midline shift).
Level 3 Underpowered class I evidence along with the
preponderance of conﬂicting class II evidence suggests
that SRS alone may provide equivalent functional and
survival outcomes compared with resection ? WBRT for
patients with single brain metastases, so long as ready
detection of distant site failure and salvage SRS are
possible.
Note The following question is fully addressed in the
WBRT guideline paper within this series by Gaspar et al.
Given that the recommendation resulting from the sys-
tematic review of the literature on this topic is also highly
relevant to the discussion of the role of surgical resection in
the management of brain metastases, this recommendation
has been included below.
Question
Does surgical resection in addition to WBRT improve
outcomes when compared with WBRT alone?
Target population
This recommendation applies to adults with a newly
diagnosed single brain metastasis amenable to surgical
resection; however, the recommendation does not apply to
relatively radiosensitive tumors histologies (i.e., small cell
lung cancer, leukemia, lymphoma, germ cell tumors and
multiple myeloma).
Recommendation
Surgical resection plus WBRT versus WBRT alone
Level 1 Class I evidence supports the use of surgical
resection plus post-operative WBRT, as compared to
WBRT alone, in patients with good performance status
(functionally independent and spending less than 50% of
time in bed) and limited extra-cranial disease. There is
insufﬁcient evidence to make a recommendation for
patients with poor performance scores, advanced systemic
disease, or multiple brain metastases.
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Rationale
A signiﬁcant proportion of adults diagnosed with cancer
will develop brain metastases. According to the 2008
American Cancer Society Registry, approximately 1.4
million Americans are diagnosed with cancer every year
[1] and up to 40% of these patients—over a half million
people annually—will go onto develop one or more brain
metastases [2]. Of these patients, approximately one-third
will be potential candidates for surgical resection.
The outcome for patients with brain metastases is gen-
erally poor, with median survivals following WBRT alone
in the range of 3–6 months [3–5]. Given this poor prog-
nosis, considerable efforts have been made to explore
additional or alternative treatment modalities that have the
potential to improve survival, quality of life and local tumor
control.
For patients with a single accessible brain metastasis,
surgical resection followed by post-operative WBRT has
been compared to WBRT alone in three randomized control
trials (RCTs) [3–5]. The evidence for this combined treat-
ment approach is reviewed in the guideline paper in this
series by Gaspar et al. [6] Because the data from these
randomized comparisons of WBRT alone, versus surgical
resection followed by post-operative WBRT, addresses the
role of surgical resection in the management of patients
with a newly diagnosed brain metastasis, this paper will
refer to this evidence in its recommendations for the role of
surgical resection.
The advent of stereotactic radiosurgery (SRS) has pro-
vided a new and less invasive local treatment modality that,
like surgical resection, has the ability to treat brain
metastases while sparing healthy brain tissue. A key area
that this paper will address is the role of surgical resection
compared to SRS in the initial management of patients with
brain metastases.
The overall objectives of this paper are:
1. To systematically review the evidence available for the
following treatment comparisons for patients with a
newly diagnosed brain metastasis. Please note that
‘‘surgery’’ implies open surgical resection.
– Surgery versus WBRT ± surgery
– Surgery ± WBRT or partial brain radiotherapy
(RT) versus SRS ± WBRT or partial brain RT
– Surgery ± WBRT versus surgery ? SRS
2. To make recommendations based on this evidence for
the role of surgery in the management of these patients.
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123Methods
Search strategy
The following electronic databases were searched from
1990 to September 2008: MEDLINE
 , Embase
 , Coch-
rane Database of Systematic Reviews, Cochrane Con-
trolled Trials Registry, and Cochrane Database of Abstracts
of Reviews of Effects. A broad search strategy using a
combination of subheadings and text words was employed.
The search strategy is documented in the methodology
paper for this guideline series by Robinson et al. [7].
Reference lists of included studies were also reviewed.
Eligibility criteria
• Published in English.
• Patients with newly diagnosed brain metastases.
• Fully-published (i.e., not in abstract form) peer-
reviewed primary comparative studies (These included
the following comparative study designs for primary
data collection: RCTs, non-randomized trials, cohort
studies and case–control studies).
• Study comparisons include one or more of the fol-
lowing:
– Surgery versus WBRT
– Surgery versus surgery ? WBRT
– Surgery ± WBRT or partial brain RT versus
SRS ± WBRT or partial brain RT
– Surgery versus surgery ? SRS
– Surgery ? WBRT versus surgery ? SRS
(Where SRS could be single session and fraction-
ated stereotactic radiotherapy)
• Number of study participants with a newly diagnosed
brain metastasis C5 per study arm for at least two of the
study arms.
• Baseline information on study participants is provided
by treatment group in studies evaluating interventions
exclusively in patients with a newly diagnosed brain
metastasis. For studies with mixed populations (i.e.,
includes participants with conditions other than newly
diagnosed brain metastases), baseline information is
provided for the intervention sub-groups of participants
with a newly diagnosed brain metastasis.
Study selection and quality assessment
Two independent reviewers evaluated citations using
a priori criteria for relevance and documented decisions in
standardized forms. Cases of disagreement were resolved
by a third reviewer. The same methodology was used for
full-text screening of potentially relevant papers. Studies
which met the eligibility criteria were data extracted by one
reviewer and the extracted information was checked by a
second reviewer. The PEDro scale [8, 9] was used to rate
the quality of randomized trials. The quality of compara-
tive studies using non-randomized designs was evaluated
using eight items selected and modiﬁed from existing
scales.
Evidence classiﬁcation and recommendation levels
Both the quality of the evidence and the strength of the
recommendations were graded according to the American
Association of Neurological Surgeons (AANS)/Congress
of Neurological Surgeons (CNS) criteria. These criteria are
provided in the methodology paper for this guideline series.
Guideline development process
The AANS/CNS convened a multi-disciplinary panel of
clinical experts to develop a series of practice guidelines on
the management of brain metastases based on a systematic
review of the literature conducted in collaboration with
methodologists at the McMaster University Evidence-
based Practice Center.
Scientiﬁc foundation
Overall, 15 publications (14 primary studies [10–23] and
one companion paper [24]) met the eligibility criteria.
Figure 1 outlines the ﬂow of studies through the review
process.
Title and Abstract Screening 
n=16,966 
Full Text Screening 
n=33 
Excluded at Title and 
Abstract 
n=16,933 
Eligible Studies 
n=15 
18 Excluded 
No extractable data…………………………………..2 
No baseline patient data by treatment group……….11 
No treatment comparison of interest……...................2 
<5 patients with brain metastases / group…….……..1 
Non-comparative study…………………………….. 1 
Mixed population group (new and recurrent BM)…..1 
15 Included 
Surgery vs. Surgery + WBRT ……………………….5 
(4 unique studies, 1 companion study) 
Surgery + WBRT vs. SRS……….……….….............3 
Surgery + WBRT vs. SRS + WBRT………...............4 
Other ………………………………………………...3 
Fig. 1 Flow of studies to ﬁnal number of eligible studies
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123Surgical resection versus surgical resection ? WBRT
One RCT [10] and three retrospective cohort studies
[11–13] evaluated surgical resection alone compared to
surgery plus post-operative WBRT for the initial manage-
ment of a single brain metastasis (Table 1).
The randomized data available to address this treatment
comparison comes from a multi-center trial conducted in
the United States by Patchell et al. [10]. The trial ran-
domized adults with Karnofsky performance scores (KPS)
C70 who had complete resection of a single biopsy-proven
brain metastasis, conﬁrmed by MRI, to post-operative
WBRT (50.4 Gy in 28 fractions) or no further treatment.
Randomization was stratiﬁed by the extent of extra-cranial
disease and primary tumor type. A total of 95 patients were
randomized: 49 patients to post-operative WBRT and 46
patients to observation. Baseline characteristics were well-
balanced between the two groups. Non-small cell lung
cancer (NSCLC) was the predominant tumor type (sur-
gery ? WBRT: 59%; surgery alone: 61%), median KPS
was 90 in both groups and approximately one-third of
patients had no evidence of extra-cranial disease (sur-
gery ? WBRT: 37%; surgery alone: 35%). No patient was
lost to follow-up and the data was analyzed by intention-
to-treat. The primary outcome was tumor recurrence any-
where in the brain.
Fewer patients who received post-operative WBRT
experiencedarecurrenceinthebraincomparedtothosewho
had surgicalresection alone [surgery ? WBRT:9/49 (18%)
versus surgery: 32/46 (70%); P\0.001]. Recurrence in the
Table 1 Surgery versus surgery ? WBRT
First author (Year) Interventions Median survival # pts with recurrence/
progression
a
Median time to
recurrence/
progression
Randomized trials
Patchell [10] (1998) G1: Surgery (n = 46)
G2: Surgery ? WBRT
(n = 49)
G1: 43 wks
G2: 48 wks
(Log-rank; P = NS)
At original site:
G1: 21/46 (46%)
G2: 5/49 (10%) (P\0.001)
Overall in brain:
G1: 32/46 (70%)
G2: 9/49 (18%) (P\0.001)
At original site:
G1: 27 wks
G2:[50 wks
(Log-rank; P\0.001)
Overall in brain:
G1: 26 wks
G2: 220 wks
(Log-rank;
P\0.001)
Retrospective cohort studies
Armstrong[11] (1994) G1: Surgery (n = 32)
G2: Surgery ? WBRT
(n = 32)
[matched to G1]
G3: Surgery ?
WBRT (n = 79)
[not matched]
G1: 14 months
G2: 10 months
G3: 15 months
(G1 vs. G2:
Log-rank; P = NS)
At original site:
G1: 11/32 (34%)
G2 ? G3: 25/111 (23%)
(G1 vs. G2 ? G3: P = NS)
Overall in brain:
G1: 38%
G2: 47%
G3: 42% (G1 vs. G2: P = NS)
NR
Hagen [12] (1990) G1: Surgery (n = 16)
G2: Surgery ? WBRT
(n = 19)
G1: 8.3 months
G2: 6.4 months
(Test not speciﬁed;
P = NS)
At original site:
G1: 6/16 (38%)
G2: 4/19 (21%) (P = NR)
Overall in brain:
G1: 11/16 (69%)
G2: 7/19 (37%) (P = NR)
At original site: NR
Overall in brain:
G1: 5.7 months
G2: 26.6 months
(Test not speciﬁed;
P\0.05)
Skibber [13] (1996) G1: Surgery (n = 12)
G2: Surgery ? WBRT
(n = 22)
G1: 6 months
G2: 18 months
(Generalized Wilcoxon;
P = 0.002)
At original site: NR
Overall in brain:
G1: 9/12 (75%)
G2: 5/22 (23%) (P = NR)
NR
G1 Group 1, G2 Group 2, G3 Group 3, NR Not reported, NS Not signiﬁcant, Pts Patients, WBRT Whole-brain radiation therapy
a Number of pts with recurrence/progression of brain metastases, unless otherwise speciﬁed
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brain metastasis [surgery ? WBRT: 5/49 (10%) versus
surgery: 21/46 (46%); P\0.001] and at distant sites in the
brain [surgery ? WBRT: 7/49 (14%) versus surgery: 17/46
(37%); P\0.01] compared to patients who did not receive
post-operative WBRT.
The time to any recurrence in the brain was signiﬁcantly
longer in the group that had post-operative WBRT com-
pared to the group that did not (log-rank; P\0.001). Both
the time to recurrence at the original site in the brain (log-
rank; P\0.001) and at distant brain sites (log-rank;
P = 0.04) were signiﬁcantly longer in the post-operative
WBRT group compared to the group that received no
further treatment following surgery.
Fewer patients in the WBRT group died as a result of
neurological causes than did patients in the surgery alone
group [surgery ? WBRT: 6/43 (14%) deaths versus sur-
gery: 17/39 (44%) deaths; P = 0.003]. Overall survival did
not differ signiﬁcantly between the two groups. Median
survival in the surgery ? WBRT group was 48 weeks
compared to 43 weeks in the group that received no further
treatment following surgical resection. This study was not
powered for survival, however, which was a secondary and
not a primary endpoint. The duration of functional inde-
pendence(deﬁnedasthe median timethat KPSremainC70)
also did not differ signiﬁcantly between the two groups
(surgery ? WBRT: 37 weeks versus surgery: 35 weeks;
P = NS).
Surgical resection ± WBRT or partial brain RT versus
stereotactic radiosurgery (SRS) ± whole or partial
brain RT
One RCT [23] and nine retrospective cohort studies
[14–22] met the eligibility criteria for this treatment com-
parison (Tables 2, 3, 4). All of these studies utilized single-
dose SRS with one exception [20] which employed frac-
tionated stereotactic radiotherapy. However, in 2006, the
American Society for Therapeutic Radiology and Oncol-
ogy (ASTRO), the American Association of Neurological
Surgeons (AANS) and the Congress of Neurological Sur-
geons (CNS) jointly agreed to deﬁne SRS in a way that
Table 2 SRS versus Surgery ? WBRT
First author (Year) Interventions Median survival # pts with recurrence/
progression
a
Median time to recurrence/
progression
Randomized controlled trials
Muacevic [23] (2008) G1: SRS (n = 31)
G2: Surgery ? WBRT
(n = 33)
G1: 10.3 months
G2: 9.5 months
(Log-rank; P = NS)
1 yr local control rate:
G1: 97%
G2: 82%
1 yr distant recurrence rate:
G1: 26%
G2: 3%
At original site:
Median: NR
(LR curves: log-rank;
P = 0.06, NS)
At distant brain sites:
Median: NR
(DR curves: log-rank;
P = 0.04)
Retrospective cohort studies
Muacevic [14] (1999) G1: SRS (n = 56)
G2: Surgery ? WBRT
(n = 52)
G1: 35 weeks
G2: 68 weeks
(Log-rank; P = NS)
1 yr freedom from LR rate:
G1: 83%
G2: 75%
1 yr freedom from DR rate:
G1: 68%
G2: 90% (P = 0.0025)
At original site:
G1: Median not reached
G2: Median not reached
(Log-rank; P = NS)
At distant brain sites:
NR
Rades [15] (2007) G1: SRS (n = 94) Median survival: NR 1 yr freedom from LR rate: At original site:
G2: Surgery ? WBRT
(n = 112)
1 yr survival rate:
G1: 54%
G2: 38%
(Log-rank; P = NS)
G1: 64%
G2: 56%
1 yr freedom from BR rate:
G1: 49%
G2: 44%
Median: NR
(LR curves: log-rank;
P = NS)
Overall in brain:
Median: NR
(BR curves: log-rank;
P = NS)
BR Brain recurrence (local ? distant), DR Distant recurrence in brain, G1 Group 1, G2 Group 2, LR Local recurrence at original site in brain,
NR Not reported, NS Not signiﬁcant, Pts Patients, SRS Stereotactic radiosurgery, WBRT Whole-brain radiation therapy
a Number of pts with recurrence/progression of brain metastases, unless otherwise speciﬁed
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dose SRS up to ﬁve doses (2–5 doses) [25, 26]. Addi-
tionally, while the majority of these SRS studies were
conducted using Gamma Knife radiosurgery, there is no
evidence to suggest that other modes of delivery of SRS
would lead to different outcomes.
(a) Surgical resection ? WBRT versus SRS
A small RCT [23] and two retrospective cohorts [14, 15]
speciﬁcally compared resection plus post-operative WBRT
to SRS alone for the initial treatment of a newly diagnosed
brain metastasis (Table 2).
The randomized data is from a multi-center RCT con-
ducted in Germany by Muacevic et al. [23], which closed
prematurely due to poor patient accrual. A total of 64 out of
the planned 242 adult patients with single, small (B3 cm)
operable brain metastases and a KPS C70 were randomized
to receive SRS alone (n = 31) or surgical resection fol-
lowed by WBRT (n = 33). Baseline prognostic variables
were well-balanced between the two groups. All of the
participants received the treatment as allocated and none
were lost to follow-up.
The primary outcome, overall survival, did not differ
signiﬁcantlybetweenthe twogroups.Median survival inthe
surgery ? WBRT group was 9.5 months, compared to
10.3 months in the group that received SRS. In terms of
secondary outcomes, duration of freedom from local recur-
rence did not signiﬁcantly differ between the two groups
(log-rank; P = 0.06; NS). The 1 year local control rate was
82% in the surgery ? WBRT group and 96.8% in the SRS
group. Freedom from recurrence at distant brain sites was
signiﬁcantly longer in the group that had surgical resection
plus WBRT compared to the group that received SRS (log-
rank; P = 0.04).Finally, the overall numberofneurological
deaths was not signiﬁcantly different between the groups.
(b) Surgical resection ? WBRT versus SRS ? WBRT
No prospective studies were identiﬁed that met the eligi-
bility criteria for this treatment comparison. Four retro-
spective cohort studies [16–19] that compared surgical
resection plus WBRT to SRS plus WBRT met the inclusion
criteria (Table 3). In two of these studies [16, 19] the
majority, but not all, of the subjects received WBRT.
In three of the studies [17–19], overall survival did not
differ signiﬁcantly between the resection plus WBRT
group compared with the group that received SRS plus
WBRT. In one study [16], overall survival was signiﬁ-
cantly longer for patients that received surgery plus WBRT
compared to patients that had SRS and WBRT (log-rank;
P = 0.0018), although patients in the SRS arm were gen-
erally poorer resection candidates. In this study, freedom
from local recurrence was also signiﬁcantly longer in
the surgery plus WBRT group (log-rank; P = 0.0001).
Schoggl et al. [18] reported a signiﬁcant beneﬁt in duration
of freedom from local recurrence for patients that received
SRS and WBRT compared to patients that had surgical
excision plus WBRT (P\0.05), supporting the ﬁndings in
the Garell et al. [17] study as well. O’Neill et al. [19]
reported no local recurrences in the SRS group compared
to a 58% local recurrence rate in the surgical resection
group (P = 0.020). These studies also demonstrated no
signiﬁcant difference between groups in the duration of
freedom from recurrence at distant brain sites [16, 18].
Surgical resection – WBRT versus surgical
resection 1 SRS
No studies were identiﬁed that met the eligibility criteria
for this treatment comparison.
Summary and discussion
Surgical resection plus WBRT versus WBRT alone
The WBRT guideline paper by Gaspar et al. [6] outlines in
detail the evidence supporting the addition of WBRT after
surgical resection. Please refer to this paper for a further
discussion of why surgical resection plus post-operative
WBRT represents a superior treatment modality as com-
pared to WBRT alone, in patients with good performance
status (functionally independent and spending less than
50% of time in bed) and limited extra-cranial disease.
There is insufﬁcient evidence to make a recommendation
for patients with poor performance scores, advanced sys-
temic disease, or multiple brain metastases.
Surgical resection ? WBRT versus surgical resection
Class I evidence is available (in the Patchell RCT [10]) to
support a level 1 recommendation for patients with a single
brain metastasis amenable to surgical resection. The class I
evidence supports the use of WBRT following surgical
resection. Control of extra-cranial disease is not required
for patients to beneﬁt from aggressive forms of local
therapy, but generally patients required a KPS of at least 70
to be eligible for the studies and the anticipated interven-
tions. Recurrence in the brain, as measured overall, at the
original site or at distant brain sites, were all signiﬁcantly
lower in the group that received adjuvant post-operative
WBRT than the group undergoing surgical resection alone.
However, both overall survival and time spent in an
independent status (KPS [70) did not differ signiﬁcantly
38 J Neurooncol (2010) 96:33–43
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reduction in neurologic deaths (P = 0.003) in the patients
who received WBRT in addition to surgical resection. In
patients with distant metastatic disease, rates of neurolog-
ical death may in fact provide a more useful endpoint for
this clinical comparison. Nonetheless, the lack of a survival
difference has offered support to a common but unsub-
stantiated treatment plan encompassing surgery alone with
close observation, delaying WBRT for so-called ‘‘salvage
therapy’’ at recurrence. No evidence-based justiﬁcation
currently exists for such expectant observation.
Surgical resection ? WBRT versus SRS
While the surgical resection versus radiosurgery compari-
son produces less clear-cut results, class I evidence based
on the AANS/CNS scale does address this clinical
question. However, the Muacevic RCT [23] closed early
and only enrolled approximately one-quarter of the pro-
posed participants and was thus underpowered to detect a
survival difference, if in fact one exists. Given the small
sample size, the authors of the RCT reported that by their
calculations, the trial was only sufﬁciently powered to
detect an overall survival difference of 38% or greater
between the two groups 80% of the time. It is difﬁcult to
offer ﬁrm guidelines based upon a prematurely closed
study.
Furthermore, duration of freedom from local recur-
rence did not signiﬁcantly differ between the two groups
(log-rank; P = 0.06; NS) with the 1 year local control
rate at 82% in the resection ? WBRT group and 96.8%
in the SRS group. A larger trial will, perhaps, provide
more deﬁnitive information regarding this outcome given
the borderline P-value of 0.06. In general, though, it is
Table 3 Surgery ? WBRT versus SRS ? WBRT
First author (Year) Interventions Median survival # pts with recurrence/progression
a Median time to
recurrence/progression
Retrospective cohort studies
Bindal [16] (1996) G1: Surgery ± WBRT
b
(n = 62) [matched to G2]
G2: SRS ± WBRT
b
(n = 31)
G1: 16.4 months
G2: 7.5 months
(Log-rank; P = 0.0018)
1 yr freedom from LR rate:
G2 poorer than G1
[Data: NR]
1 yr freedom from DR rate:
G1: 75%
G2: 69%
At original site:
G1: Median not reached
G2: 6 months
(Log-rank; P = 0.0001)
At distant brain sites:
G1: Median not reached
G2: Median not reached
(Log-rank; P = NS)
Garell [17] (1999) G1: Surgery ? WBRT
(n = 37)
G2: SRS ? WBRT (n = 8)
G1: 8 months
G2: 12.5 months
(Log-rank P = NS)
NR NR
Schoggl [18] (2000) G1: Surgery ? WBRT
(n = 66)
G2: SRS ? WBRT
(n = 67)
G1: 9 months
G2: 12 months
(Test unclear
; P = NS)
At original site:
G1: 11/66 (17%)
G2: 3/67 (5%) (P = NR)
At distant brain sites:
G1: 10/66 (15%)
G2: 7/67 (10%) (P = NR)
At original site:
G1: 3.9 months
G2: 4.9 months
(Test unclear; P\0.05)
At distant brain sites:
G1: 3.7 months
G2: 4.4 months
(Test unclear; P = NS)
O’Neill [19] (2003) G1: Surgery ± WBRT
b
(n = 74)
G2: SRS ± WBRT
b
(n = 23)
Median survival: NR
1 yr survival rate:
G1: 62%
G2: 56%
(Log-rank; P = NS)
At original site:
G1: 11/64 (17%)
G2: 0/21 (0%) (P = NR)
Overall in brain:
G1: 19/64 (30%)
G2: 6/21 (29%) (P = NR)
NR
DR Distant recurrence in brain, G1 Group 1, G2 Group 2, LR Local recurrence at original site in brain, NR Not reported, NS Not signiﬁcant,
Pts Patients, SRS Stereotactic radiosurgery, WBRT Whole-brain radiation therapy
a Number of pts with recurrence/progression of brain metastases, unless otherwise speciﬁed
b WBRT use similar at baseline in both groups
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comparing surgical resection versus SRS; in the SRS
literature, a remaining enhancing abnormality stable over
time is considered ‘‘local control,’’ but may overestimate
the true long-term control associated with SRS.
In terms of distant brain recurrence, freedom from
recurrence at distant brain sites was signiﬁcantly longer in
the group that had resection plus WBRT, as expected,
compared to the group that received local therapy in
the form of SRS (log-rank; P = 0.04). In this and other
studies, patient accrual lagged behind proposed enrollment
in the study design phase because of strong physician
preference for either surgical resection or SRS.
The lower distant brain recurrence rates in the WBRT
arm makes intuitive sense since these patients are receiving
effective treatment for potential lesions elsewhere in the
brain, unlike those in the SRS arm. In terms of survival,
however, class II evidence suggests that survival is not
decreased when WBRT is not given as initial therapy (for
details, refer to the guideline paper in this series by Linskey
et al. [27], which addresses the role of SRS for newly
diagnosed brain metastases).
Quality of life, including potential neuro-cognitive
treatment effects, represents another important question
that still needs to be addressed: does recurrence impact
quality of life since survival appears to be unchanged
between the two treatment arms? A recently-closed ran-
domized Phase III trial by the European Organization for
the Research and Treatment of Cancer (EORTC #22952)
achieved full accrual of its target 340 patients and com-
pared no radiotherapy to WBRT for 1–3 brain metastases
from solid tumor after resection or SRS; these results, when
available, may provide powerful evidence for the role of
WBRT.
Surgical resection ? WBRT versus SRS ? WBRT
Four retrospective cohort studies [16–19] provide evi-
dence for this treatment comparison. While class II evi-
dence does exist for these interventions, all of the studies
are retrospective rather than prospective, and they yield
conﬂicting results in terms of overall survival and dura-
tion of freedom from local recurrence. However, Class II
evidence does suggest that larger lesions ([3c m i n
maximum diameter) or those causing signiﬁcant mass
effect ([1 cm midline shift) may have better outcomes
with surgical resection. Radiosurgery is recommended for
single surgically inaccessible lesions measuring\3c mi n
maximum diameter.
Surgical resection ± WBRT versus surgical
resection ? SRS
No studies were identiﬁed for this treatment comparison
and as such, no evidence-based recommendations can be
made regarding one approach compared to the other.
Table 4 Other included studies of surgery ± radiotherapy versus SRS ± radiotherapy
First author (year) Interventions Median survival # pts with recurrence/
progression
a
Median time to
recurrence/progression
Retrospective cohorts
Ikushima [20] (2000) G1: Fractionated SRS (n = 10)
G2: Surgery ? RT (n = 11)
G3: RT (n = 14)
[RT = WBRT or local]
G1: 25.6 months
G2: 18.7 months
G3: 4.3 months
(Univariate analysis:
G1 vs. G2 ? G3: P = 0.05)
1 yr local control rate:
G1: 90%
G2: 88%
G3: NR
At original site:
Median: NR
(LR curves: log-rank;
P = NS)
Shinoura [21] (2002) G1: SRS (n = 28)
G2: Surgery ? RT (n = 35)
[RT = WBRT or local]
G1: 8.2 months
G2: 34.4 months
(Log-rank; P\0.0001)
# lesions that recurred at
original site:
G1: 16/52 (31%)
G2: 14/46 (30%)
(P-value: NR)
Mean time at original
site:
G1: 7.2 months
G2: 25 months
(Log-rank; P = 0.0199)
Wang [22] (2002) G1: Surgery
G2: WBRT
G3: SRS
G4: SRS ? WBRT
G1: 43 wks
G2: 37 wks
G3: 67 wks
G4: 91 wks
(Log-rank P\0.00001)
1 month local tumor
control:
G1: 89%
G2: 88%
G3: 93%
G4: 96%
NR
.
G1 Group 1, G2 Group 2, G3 Group 3, G4 Group 4, LR Local recurrence at original site in brain, NR Not reported, Pts Patients, RT Radiotherapy,
SRS Stereotactic radiosurgery, WBRT Whole-brain radiation therapy
a Number of pts with recurrence/progression of brain metastases, unless otherwise speciﬁed
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123Conclusions and future directions
Class I evidence suggests that surgical resection followed
by WBRT represents a superior treatment modality, in
terms of improving tumor control at the original site of the
metastasis and in the brain overall, when compared to sur-
gical resection alone. As reviewed by Gaspar et al., in the
WBRT guideline paper in this series, class I evidence also
supports the use of surgical resection plus post-operative
WBRTin patients with goodperformance status and limited
extra-cranial disease compared to WBRT alone (refer to the
WBRT guideline paper in this series for further detail).
The advent of SRS, though, has provided several clini-
cally important permutations and combination treatment
options for patients with brain metastases, some of which
clearly improve recurrence rates and survival as well.
Guideline papers in this series by Gaspar et al., and Lins-
key et al., address some of these relevant treatment com-
parisons incorporating surgical resection, WBRT, SRS and
the concept of delaying WBRT for salvage therapy without
adverse sequelae. Class II evidence suggests that larger
lesions ([3 cm) or those causing signiﬁcant mass effect
([1 cm midline shift) may have better outcomes with
surgical resection, whereas radiosurgery may offer slightly
better local control rates for radioresistant lesions (i.e.,
melanoma, renal cell, etc.). However, because of under-
powered class I evidence in the resection ? WBRT versus
SRS alone comparison, the authors could only make a level
3 recommendation suggesting that SRS alone may provide
equivalent functional and survival outcomes compared
with resection ? WBRT for patients with single brain
metastases, so long as ready detection of distant site failure
and salvage SRS are possible.
Additional prospective randomized studies, such as the
Phase 3 EORTC study mentioned previously (referenced
below—5) and two recently closed randomized trials
comparing surgical resection to SRS (referenced below—1,
2), will be required to more deﬁnitively assess treatment
outcomes.
One notable treatment combination in need of further
study involves the concept of applying SRS to the surgical
resection cavity post-operatively instead of post-operative
WBRT. Although many large cancer centers around the
country have recently adopted this practice, no robust
prospective data yet exists to support a few retrospective
case series suggesting that both local control rates and even
survival are enhanced by this post-operative SRS option.
The role of surgical resection for multiple brain
metastases
While surgical resection of more than one brain metas-
tasis has been performed in cases of signiﬁcant mass
effect from more than one lesion, and in cases where two
or more lesions are accessible through the same craniot-
omy approach, no robust comparative data exists to
evaluate the role of surgical resection for multiple brain
metastases. Future studies incorporating the role of
resection for more than one brain metastasis, with or
without additional adjuvant therapy, will also help clarify
whether the beneﬁts of resection discussed above apply to
multiple lesions.
Other important future directions include designing trials
with a focus on quality of life and patient functional status
as primary outcomes, rather than only recurrence rates or
survival. Given that small differences in survival rates for a
given treatment option potentially minimize signiﬁcant
differences in quality of life for a particular therapy, an
analysis of a wider range of outcome parameters may help
better inform practitioners, and our patients, when making
critical treatment decisions. Histology-speciﬁc brain
metastasis trials may also help answer important therapeutic
questions regarding radioresistant lesions versus other
common histologies. Most studies thus far have not spe-
ciﬁcally addressed differences in histological subtype
despite the fact that management of extracranial malig-
nancies differs widely based on cancer histology (i.e., breast
versus lung versus renal cell, etc.).
The following is a list of major ongoing or recently
closed clinical trials pertaining to the use of surgery that
evaluate treatment comparisons addressed by this guideline
paper for the management of newly diagnosed brain
metastases.
1. Surgery versus radiosurgery to treat metastatic brain
tumors
Ofﬁcial Title: A Prospective, Randomized Trial
Comparing Surgery Versus Radiosurgery for the
Treatment of Metastatic Brain Tumors
Status: Completed
Clinicaltrials.gov Identiﬁer: NCT00075166
Location: United States
Sponsors and Collaborators: National Institute of
Neurological Disorders and Stroke (NINDS)
2. 2. Surgery versus stereotactic radiosurgery in the
treatment of single brain metastasis: a randomized trial
Ofﬁcial Title: Surgery Versus Stereotactic Radiosur-
gery in the Treatment of Single Brain Metastasis: A
Randomized Trial
Status: Completed
Clinicaltrials.gov Identiﬁer: NCT00460395
Principal Investigator: Frederick F. Lang, M.D.,
University Of Texas MD Anderson Cancer Center
Location: United States
Sponsors and Collaborators: M.D. Anderson Cancer
Center
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1233. A Trial of Postoperative Whole Brain Radiation
Therapy versus Salvage Stereotactic Radiosurgery
Therapy for Metastasis
Ofﬁcial Title: Randomized Phase III Trial of Postop-
erative Whole Brain Radiation Therapy Compared
With Salvage Stereotactic Radiosurgery in Patients
With One to Four Brain Metastasis: Japan Clinical
Oncology Group Study (JCOG 0504)
Status: Recruiting (Phase III)
Clinicaltrials.gov Identiﬁer: NCT00280475
Principal Investigator: Takamasa Kayama, MD, PhD
Yamagata University Faculty of Medicine
Location: Japan (21 locations)
Sponsors and Collaborators: Japan Clinical Oncol-
ogy Group, Japanese Ministry of Health, Labor and
Welfare
4. A Trial Comparing Radiosurgery With Surgery for
Solitary Brain Metastases
Ofﬁcial Title: A Randomised Trial of Surgery Plus
Whole Brain Radiotherapy (WBRT) Versus Radiosur-
gery Plus WBRT for Solitary Brain Metastases
Status: Recruiting (Phase III)
Clinicaltrials.gov Identiﬁer: NCT00124761
Principal Investigator: Daniel Roos, FRANZCR, Royal
Adelaide Hospital
Location: Australia
Sponsors and Collaborators: Royal Adelaide
Hospital
5. Adjuvant Radiation Therapy in Treating Patients With
Brain Metastases
Ofﬁcial Title: Phase III Trial on Convergent Beam
Irradiation of Cerebral Metastases
Status: Active, not recruiting (Phase III)
Clinicaltrials.gov Identiﬁer: NCT00002899
Principal Investigators: Rolf-Peter Mueller, MD
Medizinische Universitaetsklinik I at the University
of Cologne Riccardo Sofﬁetti, MD Universita Degli
Studi di Turin
Location: Europe (33 locations)
Sponsors and Collaborators: European Organization
for Research and Treatment of Cancer
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